Articles published by Merck & Co., Inc.
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
June 03, 2023
Merck Announces First-Quarter 2023 Financial Results
April 27, 2023
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
April 16, 2023
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
March 06, 2023
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
February 28, 2023
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
February 24, 2023